CSF1R and neoplasm: Concerning the effect of pharmacologic M-CSFR blockade on primary tumor growth, the M-CSFR tyrosine kinase inhibitor Ki20227 was described to reduce TAM content of tumors and retard tumor cell proliferation in osteosarcoma (102) and similar results were reported for GW2580 in papillary thyroid cancer (103).